These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 27862227)

  • 1. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
    Yagami A; Furue M; Togawa M; Saito A; Hide M
    J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
    Hide M; Yagami A; Togawa M; Saito A; Furue M
    Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial.
    Okubo K; Gotoh M; Togawa M; Saito A; Ohashi Y
    Auris Nasus Larynx; 2017 Jun; 44(3):294-301. PubMed ID: 27561709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study.
    Serra E; Campo C; Novák Z; Majorek-Olechowska B; Pulka G; García-Bea A; Labeaga L
    J Dermatolog Treat; 2020 May; 31(3):270-278. PubMed ID: 30835579
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: A 12-month, multicenter, open-label clinical trial.
    Hide M; Suzuki T; Tanaka A; Aoki H
    J Dermatol Sci; 2019 Jun; 94(3):339-345. PubMed ID: 31196788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study.
    Zuberbier T; Oanta A; Bogacka E; Medina I; Wesel F; Uhl P; Antépara I; Jáuregui I; Valiente R;
    Allergy; 2010 Apr; 65(4):516-28. PubMed ID: 19860762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of bilastine: 2nd generation H1-antihistamines.
    Scaglione F
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.
    Demonte A; Guanti MB; Liberati S; Biffi A; Fernando F; Fainello M; Pepe P
    Eur Rev Med Pharmacol Sci; 2018 Feb; 22(3):820-828. PubMed ID: 29461615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
    Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
    Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
    Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
    Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
    Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
    Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving.
    Jáuregui I; Ramaekers JG; Yanai K; Farré M; Redondo E; Valiente R; Labeaga L
    Expert Opin Drug Saf; 2016 Jan; 15(1):89-98. PubMed ID: 26571227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
    Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
    Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bilastine for the relief of allergy symptoms.
    Sádaba Díaz de Rada B; Azanza Perea JR; Gomez-Guiu Hormigos A
    Drugs Today (Barc); 2011 Apr; 47(4):251-62. PubMed ID: 21573249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How bilastine is used to treat allergic rhinitis and urticaria in children.
    Rodríguez Del Río P; Rodríguez Fernández F; Ballester Asensio E; Tortajada-Girbés M
    Immunotherapy; 2022 Jan; 14(1):77-89. PubMed ID: 34850647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
    Wolthers OD
    Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bilastine: in allergic rhinitis and urticaria.
    Carter NJ
    Drugs; 2012 Jun; 72(9):1257-69. PubMed ID: 22686617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria.
    Jáuregui I; García-Lirio E; Soriano AM; Gamboa PM; Antépara I
    Expert Rev Clin Immunol; 2012 Jan; 8(1):33-41. PubMed ID: 22149338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.